In this Feb. 27, 2020, file photo, the DoorDash app is shown on a smartphone in New York. (AP Photo, File)
One of the largest delivery platforms in the U.S., DoorDash is getting into the growing prescription drug delivery business through a partnership with wholesale giant Sam's Club.
“Our partnership with DoorDash to launch this new service allows us to not only give our members more convenient healthcare options, but also delivers on our commitment to their overall wellness needs,” said John McDowell, vice president of pharmacy operations and divisional merchandise at Sam’s Club, in a statement.
DoorDash is tapping Drive, its white-label fulfillment platform for merchants, to power the partnership, which emerged specifically to meet shifting consumer expectations amid COVID.
“Businesses have evolved amidst the pandemic to prioritize the safety of their communities and to adapt to new consumer habits, and our goal is to help merchants meet those demands in a way that’s best for their business,” said Christopher Payne, chief operating officer at DoorDash.
The coronavirus pandemic has accelerated the adoption of prescription drug delivery services. Pharmacies in particular have turned to third parties to compete with online retailers.
For DoorDash, the partnership comes as the platform teams up with other companies outside of the food category, including PetSmart, Macy's, Walgreens, CVS Pharmacy, and 7-Eleven.
DoorDash will provide same-day delivery across Sam Club's 500 locations.
Sam's Club is offering free delivery on their first two pharmacy orders until the end of the year and then charging a flat fee of $7.99 per order.
Exclusive: Behr’s Andy Lopez reveals how ChatHUE, a bold collaboration with Google, is using AI to transform how we explore, choose, and connect with color.
Brian Vendig, President & CIO of MJP Wealth Advisors, joins to break down Q2 bank earnings and what they signal for markets, investors, and the economy ahead.
Are Gen Z and Millennials done with alcohol? Bacardi's Tony Latham breaks down trends, new preferences, and insights from the 2025 Cocktail Trends Report.
Comscore’s Paul Dergarabedian breaks down the battle of summer blockbusters, from Superman to Jurassic World and Fantastic Four and what it means for studios.
VENU CEO JW Roth breaks ground on a 20,000-seat, state-of-the-art amphitheater in Texas—part of a $300M public-private expansion to redefine live music.
Despite healthcare spending cuts, medtech stocks like Edwards Life Sciences, Stryker, and Boston Scientific are rising, especially those serving older pati
Joby CPO Eric Allison discusses the UAE’s historic EVTOL take off, marking Dubai as the launchpad for global air taxi adoption and Joby’s commercial readiness.
CFRA’s Angelo Zino joins us to unpack Meta’s Superintelligence Labs and what it means for the future of AI, innovation, and the company’s bold new direction.
